-
1
-
-
0029741919
-
Aromatase inhibitors and breast cancer
-
Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23(Suppl 9):10-20.
-
(1996)
Semin Oncol
, vol.23
, Issue.9 SUPPL.
, pp. 10-20
-
-
Brodie, A.M.H.1
Njar, V.C.O.2
-
2
-
-
0029783837
-
Aromatase inhibitors in clinical practice: Current status and a look to the future
-
Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol 1996;23(Suppl 9):33-8.
-
(1996)
Semin Oncol
, vol.23
, Issue.9 SUPPL.
, pp. 33-38
-
-
Harvey, H.A.1
-
3
-
-
8944237006
-
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
-
Buzdar A, Jonat W, Howell A, Jones S-E, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2000-2011
-
-
Buzdar, A.1
Jonat, W.2
Howell, A.3
Jones, S.-E.4
Blomqvist, C.5
Vogel, C.L.6
-
4
-
-
0029804714
-
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer
-
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
-
(1996)
Br J Cancer
, vol.74
, pp. 1286-1291
-
-
Geisler, J.1
King, N.2
Dowsett, M.3
Ottestad, L.4
Lundgren, S.5
Walton, P.6
-
5
-
-
0030040104
-
Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers
-
Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996;73:543-8.
-
(1996)
Br J Cancer
, vol.73
, pp. 543-548
-
-
Yates, R.A.1
Dowsett, M.2
Fisher, G.V.3
Selen, A.4
Wyld, P.J.5
-
6
-
-
0031054095
-
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
-
Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997;79:730-9.
-
(1997)
Cancer
, vol.79
, pp. 730-739
-
-
Buzdar, A.U.1
Jones, S.E.2
Vogel, C.L.3
Wolter, J.4
Plourde, P.5
Webster, A.6
-
7
-
-
9244245282
-
A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
-
Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 404-412
-
-
Jonat, W.1
Howell, A.2
Blomqvist, C.3
Eiermann, W.4
Winblad, G.5
Tyrrell, C.6
-
8
-
-
0017345746
-
Assessment of response to therapy in advanced breast cancer
-
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
-
(1977)
Cancer
, vol.39
, pp. 1289-1294
-
-
Hayward, J.L.1
Carbone, P.P.2
Heuson, J.-C.3
Kumaoka, S.4
Segaloff, A.5
Rubens, R.D.6
-
9
-
-
0023708345
-
The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
-
Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
-
(1988)
Eur J Cancer Clin Oncol
, vol.24
, pp. 1567-1572
-
-
Howell, A.1
Mackintosh, J.2
Jones, M.3
Redford, J.4
Wagstaff, J.5
Sellwood, R.A.6
-
10
-
-
0024573833
-
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
-
Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blarney RW. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989;25:469-75.
-
(1989)
Eur J Cancer Clin Oncol
, vol.25
, pp. 469-475
-
-
Robertson, J.F.R.1
Williams, M.R.2
Todd, J.3
Nicholson, R.I.4
Morgan, D.A.L.5
Blarney, R.W.6
-
11
-
-
0029856576
-
Formestane: A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
-
Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996;9:292-306.
-
(1996)
Drugs Aging
, vol.9
, pp. 292-306
-
-
Wiseman, L.R.1
Goa, K.L.2
-
12
-
-
0029940269
-
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma
-
Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 1996;77:2503-13.
-
(1996)
Cancer
, vol.77
, pp. 2503-2513
-
-
Buzdar, A.U.1
Smith, R.2
Vogel, C.3
Bonomi, P.4
Keller, A.M.5
Favis, G.6
-
13
-
-
0342595293
-
Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA)
-
Smith I, Dombernowsky P, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) (Abstract PP-8-3|. Eur J Cancer 1996;32A: (Suppl 2):49.
-
(1996)
Eur J Cancer
, vol.32 A
, Issue.2 SUPPL.
, pp. 49
-
-
Smith, I.1
Dombernowsky, P.2
Falkson, G.3
Leonard, R.4
Panasci, L.5
Bellmunt, J.6
-
14
-
-
0003354802
-
Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen
-
Goss P, Wine E, Tannock I, Schwartz IH, Kremer AB, and study group. Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen [Abstract 542]. Proc ASCO 1997;16:155a.
-
(1997)
Proc ASCO
, vol.16
-
-
Goss, P.1
Wine, E.2
Tannock, I.3
Schwartz, I.H.4
Kremer, A.B.5
-
15
-
-
0000707927
-
Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens
-
Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens [Abstract 544]. Proc ASCO 1997;16:156a.
-
(1997)
Proc ASCO
, vol.16
-
-
Marty, M.1
Gershanovich, M.2
Campos, B.3
Romieu, G.4
Lurie, H.5
Bonaventura, T.6
-
16
-
-
0000237541
-
Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen
-
Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [Abstract 543]. Proc ASCO 1997;16: 155a.
-
(1997)
Proc ASCO
, vol.16
-
-
Bergh, J.1
Bonneterre, J.2
Illiger, H.J.3
Murray, R.4
Nortier, J.5
Paridaens, R.6
-
17
-
-
0024041157
-
Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association
-
Muss HB, Wells B, Paschold EH, Black WR, Cooper MR, Capizzi RL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6: 1098-106.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1098-1106
-
-
Muss, H.B.1
Wells, B.2
Paschold, E.H.3
Black, W.R.4
Cooper, M.R.5
Capizzi, R.L.6
-
18
-
-
0025169549
-
High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association
-
Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-805.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1797-1805
-
-
Muss, H.B.1
Case, L.D.2
Capizzi, R.L.3
Cooper, M.R.4
Cruz, J.5
Jackson, D.6
-
19
-
-
0003299006
-
Efficacy of anastrozole (Arimidex) in a consecutive series of advanced breast cancer patients: M. D. Anderson Cancer Center (MDACC) experience
-
Michaud LB, Knoche AJ, Abbott B, Buzdar AU, Tashima C. Efficacy of anastrozole (Arimidex) in a consecutive series of advanced breast cancer patients: M. D. Anderson Cancer Center (MDACC) experience [Abstract 641]. Proc ASCO 1997; 16:183a.
-
(1997)
Proc ASCO
, vol.16
-
-
Michaud, L.B.1
Knoche, A.J.2
Abbott, B.3
Buzdar, A.U.4
Tashima, C.5
|